https://www.pharmaradar360.com/article/okyo-s-urcosimod-gets-fda-nod-moves-to-global-phase-3-trial-for-ncp-e3ef06f6cd0c5a2ePharma Surgeen2026-07-10T11:13:34.000ZOKYO's urcosimod gets FDA nod, moves to global phase 3 trial for NCPhttps://www.pharmaradar360.com/article/non-profit-dndi-preps-phase-3-trials-for-dengue-antibody-02566cfbab034ee1Pharma Surgeen2026-07-10T11:08:19.000ZNon-profit DNDi preps phase 3 trials for dengue antibodyhttps://www.pharmaradar360.com/article/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-d75ce56e167c69c3Pharma Surgeen2026-07-10T11:00:31.000ZGSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient populationhttps://www.pharmaradar360.com/article/decision-human-and-veterinary-medicines-register-of-licensed-manufacturing-sites-48cc8110c5fb4692Pharma Surgeen2026-07-10T10:59:20.000ZDecision: Human and veterinary medicines: register of licensed manufacturing siteshttps://www.pharmaradar360.com/article/notice-register-of-brokers-authorised-to-deal-in-human-medicines-e585a5b1747623a5Pharma Surgeen2026-07-10T10:59:07.000ZNotice: Register of brokers authorised to deal in human medicineshttps://www.pharmaradar360.com/article/decision-medicines-new-manufacturing-and-wholesale-dealer-licences-f98698f7dbd1470bPharma Surgeen2026-07-10T10:59:01.000ZDecision: Medicines: new manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/decision-human-medicines-register-of-licensed-wholesale-distribution-sites-abe6f33fdfa7e172Pharma Surgeen2026-07-10T10:58:58.000ZDecision: Human medicines: register of licensed wholesale distribution siteshttps://www.pharmaradar360.com/article/notice-medicines-terminated-and-cancelled-manufacturing-and-wholesale-dealer-lic-b2bec9e140af5c62Pharma Surgeen2026-07-10T10:58:55.000ZNotice: Medicines: terminated and cancelled manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-artemis-008-trial-of-risvutatug-rezetecan-4839c545a38faa78Pharma Surgeen2026-07-10T10:50:09.000ZHansoh Pharmaceutical : PHARMA ANNOUNCES ARTEMIS-008 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN SMALL CELL LUNG CANCERhttps://www.pharmaradar360.com/article/fda-criticizes-lundbeck-websites-are-false-or-misleading-02e72e332dd4ed4cPharma Surgeen2026-07-10T10:46:03.000ZFDA criticizes Lundbeck: Websites are “false or misleading”https://www.pharmaradar360.com/article/tobacco-and-vapes-packaging-appearance-and-display-b0f65b22298b2fc9Pharma Surgeen2026-07-10T10:45:08.000ZTobacco and vapes: packaging, appearance and displayhttps://www.pharmaradar360.com/article/standardised-packaging-for-all-tobacco-products-bf1d6af268a6e049Pharma Surgeen2026-07-10T10:45:08.000ZStandardised packaging for all tobacco productshttps://www.pharmaradar360.com/article/evonik-invests-100m-to-modernise-indiana-api-facility-505493fba91a4d94Pharma Surgeen2026-07-10T10:38:59.000ZEvonik invests $100m to modernise Indiana API facilityhttps://www.pharmaradar360.com/article/5cda0bceb58dbe1fPharma Surgeen2026-07-10T10:24:27.000ZΠρόσκληση Εκδήλωσης Ενδιαφέροντος για σύσταση και στελέχωση της Επιτροπής Ελέγχου του Εθνικού Οργανισμού Φαρμάκων.https://www.pharmaradar360.com/article/pharmaceutical-drying-equipment-market-forecast-points-higher-toward-2035-driven-dbc7930f04b71ee6Pharma Surgeen2026-07-10T10:11:12.000ZPharmaceutical Drying Equipment Market Forecast Points Higher Toward 2035, Driven by Biologics Pipeline Expansionhttps://www.pharmaradar360.com/article/mdd-class-iii-surgipro-surgipro-ii-dermalon-v-loc-90-v-loc-180-ee4d78e6f552f6f4Pharma Surgeen2026-07-10T10:09:08.000ZΑνάκληση παρτίδων των Ιατροτεχνολογικών προϊόντων κατηγορίας MDD Class III, ραμμάτων Surgipro, Surgipro II, Dermalon, V-Loc 90 και V-Loc 180https://www.pharmaradar360.com/article/annovis-bio-nyse-anvs-completes-enrollment-in-850-patient-phase-3-alzheimer-s-st-cec90760bd3eeac9Pharma Surgeen2026-07-10T10:03:18.000ZAnnovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s studyhttps://www.pharmaradar360.com/article/roche-drops-two-huntington-s-programs-after-tominersen-miss-7a28f3bd454039dbPharma Surgeen2026-07-10T09:19:58.000ZRoche drops two Huntington’s programs after tominersen misshttps://www.pharmaradar360.com/article/five-reputable-pharmaceutical-packaging-machine-manufacturers-in-china-2026-adva-2320972a9dc01b4cPharma Surgeen2026-07-10T09:13:00.000ZFive Reputable Pharmaceutical Packaging Machine Manufacturers in China 2026: Advancing Efficient Packaging Solutionshttps://www.pharmaradar360.com/article/gattefosse-accelerates-production-ramp-up-at-its-lufkin-facility-with-eight-vali-2957905623c2f931Pharma Surgeen2026-07-10T09:12:06.000ZGattefossé accelerates production ramp-up at its Lufkin facility with eight validated ingredientshttps://www.pharmaradar360.com/article/korea-s-hlb-fails-to-win-fda-approval-on-liver-cancer-drug-for-third-time-stocks-f5abed863ccf3cdbPharma Surgeen2026-07-10T09:05:55.000ZKorea’s HLB fails to win FDA approval on liver cancer drug for third time; stocks hit 9-month lowhttps://www.pharmaradar360.com/article/human-capital-report-2026-85456b473f9cab77Pharma Surgeen2026-07-10T09:00:00.000Z人を生かす力が、未来を創る 社員とともに進める人的資本経営─Human Capital Report 2026発行のお知らせhttps://www.pharmaradar360.com/article/2026-a83acd67bf22a88bPharma Surgeen2026-07-10T08:58:14.000ZΓενόσημα Απριλίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/4d391bbdaa31e7caPharma Surgeen2026-07-10T08:51:15.000ZΑΝΑΚΟΙΝΩΣΗ – ΔΙΑΚΟΠΗ ΗΛΕΚΤΡΟΝΙΚΩΝ ΥΠΗΡΕΣΙΩΝhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-s-stock-price-soars-to-8-11-hkd-marking-a-robust-3-44-9c21bb729bb8c56ePharma Surgeen2026-07-10T08:41:03.000ZCSPC Pharmaceutical Group's Stock Price Soars to 8.11 HKD, Marking a Robust 3.44% Increasehttps://www.pharmaradar360.com/article/blood-tissue-and-organ-donors-surveillance-schemes-138d59cdd1f5d36dPharma Surgeen2026-07-10T08:30:02.000ZBlood, tissue and organ donors: surveillance schemeshttps://www.pharmaradar360.com/article/tetanus-in-england-annual-reports-55f6cea4b8ae62acPharma Surgeen2026-07-10T08:30:02.000ZTetanus in England: annual reportshttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-letter-72db639854c86c3cPharma Surgeen2026-07-10T08:30:02.000ZMeningococcal B (MenB) time limited vaccination offer letterhttps://www.pharmaradar360.com/article/hiv-yorkshire-and-humber-annual-data-spotlight-42ac168b52c26834Pharma Surgeen2026-07-10T08:30:02.000ZHIV: Yorkshire and Humber annual data spotlighthttps://www.pharmaradar360.com/article/bloodborne-infections-in-blood-tissue-and-organ-donors-bibd-guidance-data-and-an-326db28ff1cc42c9Pharma Surgeen2026-07-10T08:30:02.000ZBloodborne infections in blood, tissue and organ donors (BIBD): guidance, data and analysishttps://www.pharmaradar360.com/article/price-to-earnings-ratio-of-shaanxi-micot-pharmaceutical-technology-co-ltd-class-301908f0df855a2fPharma Surgeen2026-07-10T08:23:29.000ZPrice to earnings ratio of Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H – HKEX:2335https://www.pharmaradar360.com/article/pharmaceutical-3pl-market-size-share-growth-forecast-2034-b7de7ce36bdd3f1dPharma Surgeen2026-07-10T08:20:07.000ZPharmaceutical 3PL Market Size, Share | Growth Forecast [2034]https://www.pharmaradar360.com/article/price-to-sales-forward-of-beijing-sl-pharmaceutical-co-ltd-class-a-szse-002038-6838a881454d0f67Pharma Surgeen2026-07-10T08:18:56.000ZPrice to sales forward of Beijing SL Pharmaceutical Co. Ltd. Class A – SZSE:002038https://www.pharmaradar360.com/article/find-product-information-about-medicines-310bab551e083dcfPharma Surgeen2026-07-10T08:02:04.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/first-aid-a-new-idea-for-the-biotech-act-73f597158e4db8d7Pharma Surgeen2026-07-10T07:42:43.000ZFIRST AID: A new idea for the Biotech Acthttps://www.pharmaradar360.com/article/hanmi-pharm-s-phase-2-melanoma-trial-advances-as-planned-1a27dbc39612fb77Pharma Surgeen2026-07-10T07:05:07.000ZHanmi Pharm's phase 2 melanoma trial advances as plannedhttps://www.pharmaradar360.com/article/pharmequip-commits-to-deliver-high-performance-heat-exchange-solutions-for-austr-41f9872223d01899Pharma Surgeen2026-07-10T07:02:18.000ZPharmEquip Commits to Deliver High-Performance Heat Exchange Solutions for Australia's Pharmaceutical and Bioprocess Industrieshttps://www.pharmaradar360.com/article/we-have-better-antihistamines-0150ec4d101ff5b1Pharma Surgeen2026-07-10T07:00:00.000ZWe have better antihistamineshttps://www.pharmaradar360.com/article/cordis-project-digital-dashboards-in-diagnostic-innovations-98c7b78652f02f28Pharma Surgeen2026-07-10T06:50:39.000ZCORDIS project: DIGITAL DASHBOARDS IN DIAGNOSTIC INNOVATIONShttps://www.pharmaradar360.com/article/astrazeneca-signs-potential-usd-1-9bn-deal-with-china-s-sino-dd9868a11c92d889Pharma Surgeen2026-07-10T06:38:13.000ZAstraZeneca signs potential USD 1.9bn deal with China's Sinohttps://www.pharmaradar360.com/article/3-psychedelic-stocks-with-potential-clinical-trial-catalysts-1da6f6918ebf402fPharma Surgeen2026-07-10T06:23:39.000Z3 Psychedelic Stocks With Potential Clinical Trial Catalystshttps://www.pharmaradar360.com/article/ibt-portfolio-manager-biotech-m-a-boom-set-to-continue-as-big-pharma-hunts-3458acba983fc104Pharma Surgeen2026-07-10T06:22:56.000ZIBT portfolio manager: biotech M&A boom set to continue as big pharma huntshttps://www.pharmaradar360.com/article/biotech-cameras-make-roads-safer-fd55bd952b675769Pharma Surgeen2026-07-10T06:13:23.000ZBiotech Cameras Make Roads Saferhttps://www.pharmaradar360.com/article/us-s-biotech-scrutiny-tests-china-s-drugmakers-abroad-d54d9f9bc91ea8e7Pharma Surgeen2026-07-10T06:07:22.000ZUS’s biotech scrutiny tests China’s drugmakers abroadhttps://www.pharmaradar360.com/article/hlb-liver-cancer-drug-hits-fda-setback-again-over-manufacturing-issues-c4920f757f0e2a62Pharma Surgeen2026-07-10T05:54:38.000ZHLB liver cancer drug hits FDA setback again over manufacturing issueshttps://www.pharmaradar360.com/article/waycen-partners-with-daewoong-to-expand-ai-endoscopy-market-eb15a977afb1b1dePharma Surgeen2026-07-10T05:44:54.000ZWaycen partners with Daewoong to expand AI endoscopy markethttps://www.pharmaradar360.com/article/abobotulinumtoxina-meets-primary-end-points-in-phase-3-program-for-both-episodic-d645061362f3736dPharma Surgeen2026-07-10T05:37:04.000ZAbobotulinumtoxinA Meets Primary End Points in Phase 3 Program for Both Episodic and Chronic Migrainehttps://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-shares-up-16-1-what-s-next-2aba87ea3f453c20Pharma Surgeen2026-07-10T04:22:40.000ZOncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1% - What's Next?https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-amchepry-9b2c6c6fbacbbd29Pharma Surgeen2026-07-10T03:00:00.000Z[SHINSA]English Translation of Review Report: AMCHEPRYhttps://www.pharmaradar360.com/article/kokusai-pmda-updates-2026-no-2-posted-080e4a2b9cea0830Pharma Surgeen2026-07-10T03:00:00.000Z[KOKUSAI]PMDA Updates (2026 No.2) postedhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-f223477db0ccc54ePharma Surgeen2026-07-10T02:48:26.000ZPrice to sales forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/hlb-receives-fda-crl-for-rivoceranib-as-manufacturing-issues-delay-approval-ef62659cb9aa38c5Pharma Surgeen2026-07-10T02:05:28.000ZHLB Receives FDA CRL for Rivoceranib as Manufacturing Issues Delay Approvalhttps://www.pharmaradar360.com/article/hlb-plunges-to-daily-limit-at-open-after-fda-issues-third-crl-for-liver-cancer-d-fc72b742efb218aaPharma Surgeen2026-07-10T01:55:00.000ZHLB Plunges to Daily Limit at Open After FDA Issues Third CRL for Liver Cancer Drughttps://www.pharmaradar360.com/article/zhangjiang-pharma-valley-fuels-biotech-momentum-2d9713df745c260bPharma Surgeen2026-07-10T01:50:11.000ZZhangjiang Pharma Valley fuels biotech momentumhttps://www.pharmaradar360.com/article/astrazeneca-heart-drug-misses-phase-3-goal-as-design-woes-sink-shares-chosunbiz-a25e8cfd96d0ce1cPharma Surgeen2026-07-10T00:51:00.000ZAstraZeneca heart drug misses phase 3 goal as design woes sink shares - CHOSUNBIZhttps://www.pharmaradar360.com/article/otsuka-pharmaceutical-factory-announces-expansion-of-iv-solutions-manufacturing-c0acab21aec7cb80Pharma Surgeen2026-07-10T00:00:00.000ZOtsuka Pharmaceutical Factory Announces Expansion of IV Solutions Manufacturing Capacity in North America Advancing Supply Stability and Development of DEHP-Free IV Containershttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-19b1e119e8c27acbPharma Surgeen2026-07-10T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-d0ecf85fc832d3adPharma Surgeen2026-07-10T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-3ad5323e87c281c3Pharma Surgeen2026-07-10T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-6e69afddb0db372dPharma Surgeen2026-07-10T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-95b22729ba8f5e24Pharma Surgeen2026-07-10T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-bfe77325f368efa7Pharma Surgeen2026-07-10T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-6ca148201525d57dPharma Surgeen2026-07-10T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-ca3c7fc35332364cPharma Surgeen2026-07-10T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-c59c5e45b8e93a9fPharma Surgeen2026-07-10T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-a0794bf15fdbf788Pharma Surgeen2026-07-10T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-4aacbc9526093254Pharma Surgeen2026-07-10T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-fbd59eb619f14c41Pharma Surgeen2026-07-10T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-2c25cc7314deefb1Pharma Surgeen2026-07-10T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-0af3f3ef2b86e843Pharma Surgeen2026-07-10T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/timothy-genetta-d-o-decision-and-order-858014d7ff7959bcPharma Surgeen2026-07-10T00:00:00.000ZTimothy Genetta, D.O.; Decision and Orderhttps://www.pharmaradar360.com/article/ruth-jones-d-o-decision-and-order-7376c48cad3f11b5Pharma Surgeen2026-07-10T00:00:00.000ZRuth Jones, D.O.; Decision and Orderhttps://www.pharmaradar360.com/article/mariana-moualem-f-n-p-decision-and-order-0b95a1f3dc6288bfPharma Surgeen2026-07-10T00:00:00.000ZMariana Moualem, F.N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/mark-allen-d-d-s-decision-and-order-6ee03d311a438c8dPharma Surgeen2026-07-10T00:00:00.000ZMark Allen, D.D.S.; Decision and Orderhttps://www.pharmaradar360.com/article/frederick-tanzer-m-d-decision-and-order-b2ce0b41c792a214Pharma Surgeen2026-07-10T00:00:00.000ZFrederick Tanzer, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/charter-re-establishment-for-the-national-advisory-committee-on-rural-health-and-bf3aeb8cf92cae87Pharma Surgeen2026-07-10T00:00:00.000ZCharter Re-Establishment for the National Advisory Committee on Rural Health and Human Serviceshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-national-human-trafficking-62bd316879dfceacPharma Surgeen2026-07-10T00:00:00.000ZSubmission for Office of Management and Budget Review; National Human Trafficking Training and Technical Assistance Center Evaluation Packagehttps://www.pharmaradar360.com/article/meeting-of-the-advisory-board-on-radiation-and-worker-health-national-institute-aa80b564b17b64a8Pharma Surgeen2026-07-10T00:00:00.000ZMeeting of the Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Healthhttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-application-from-the-joint-commission-for-continu-36896811c8ee47c5Pharma Surgeen2026-07-10T00:00:00.000ZMedicare and Medicaid Programs; Application From The Joint Commission for Continued CMS Approval of Its Home Health Agency (HHA) Accreditation Programhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-964b4c71713a2f8dPharma Surgeen2026-07-10T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Healthy Start Evaluation and Quality Improvement, OMB No. 0915-0338-Revisionhttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-income-withholding-for-sup-ac0c6109c09ec6ddPharma Surgeen2026-07-10T00:00:00.000ZSubmission for Office of Management and Budget Review; Income Withholding for Supporthttps://www.pharmaradar360.com/article/comparison-of-quantitative-prediction-methods-for-drug-drug-interactions-based-o-5f3c57e5c5d5e3edPharma Surgeen2026-07-10T00:00:00.000ZComparison of Quantitative Prediction Methods for Drug–Drug Interactions Based on Cytochrome P450 Inhibitionhttps://www.pharmaradar360.com/article/the-nurse-role-in-early-mobilization-in-icu-a-brazilian-perspective-on-recovery-2d86f797c817470bPharma Surgeen2026-07-10T00:00:00.000ZThe nurse role in early mobilization in ICU: A Brazilian perspective on recovery-oriented critical carehttps://www.pharmaradar360.com/article/unmet-needs-and-polypharmacy-as-key-drivers-of-drug-therapy-problems-among-cardi-f344f2bb6b401560Pharma Surgeen2026-07-10T00:00:00.000ZUnmet needs and polypharmacy as key drivers of drug therapy problems among cardiac patients at a tertiary hospital: a cross-sectional studyhttps://www.pharmaradar360.com/article/magnesium-sulfate-gargle-for-preventing-postoperative-sore-throat-following-lary-71cc06da6884b6f3Pharma Surgeen2026-07-10T00:00:00.000ZMagnesium sulfate gargle for preventing postoperative sore throat following laryngeal mask airway ventilation: a randomized, controlled, dose-finding trialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-cytokine-profiles-for-early-prediction-of-severe-my-8c31606bac781161Pharma Surgeen2026-07-10T00:00:00.000ZClinical characteristics and cytokine profiles for early prediction of severe Mycoplasma pneumoniae pneumonia in children: a prospective cohort studyhttps://www.pharmaradar360.com/article/a-study-of-the-utilization-pattern-of-antihypertensive-drugs-in-a-tertiary-care-c62d90c6ca77c568Pharma Surgeen2026-07-10T00:00:00.000ZA Study of the Utilization Pattern of Antihypertensive Drugs in a Tertiary Care Teaching Hospitalhttps://www.pharmaradar360.com/article/a-retrospective-analysis-of-skin-biopsies-over-one-year-age-sex-distribution-and-ba8a16b36ad1f373Pharma Surgeen2026-07-10T00:00:00.000ZA Retrospective Analysis of Skin Biopsies Over One Year: Age, Sex Distribution, and Histopathological Patternshttps://www.pharmaradar360.com/article/analysis-of-acute-kidney-injury-in-patients-with-sepsis-under-icu-03560292f45fe2caPharma Surgeen2026-07-10T00:00:00.000ZAnalysis of Acute Kidney Injury in Patients with Sepsis Under ICUhttps://www.pharmaradar360.com/article/pravastatin-for-prevention-of-preterm-birth-in-high-risk-pregnancies-a-pilot-ran-00c7adb1bc3551e5Pharma Surgeen2026-07-10T00:00:00.000ZPravastatin for Prevention of Preterm Birth in High-Risk Pregnancies: A Pilot Randomized Controlled Trialhttps://www.pharmaradar360.com/article/antibody-drug-conjugates-for-advanced-recurrent-high-grade-endometrial-cancer-po-781431bbeb1c99fdPharma Surgeen2026-07-10T00:00:00.000ZAntibody-drug conjugates for advanced/recurrent high-grade endometrial cancer: potential targets, strategies and challengeshttps://www.pharmaradar360.com/article/research-visibility-in-physical-therapy-a-narrative-analysis-of-academic-and-cli-cffbe628cc0795aaPharma Surgeen2026-07-10T00:00:00.000ZResearch Visibility in Physical Therapy: A Narrative Analysis of Academic and Clinical Contributionshttps://www.pharmaradar360.com/article/psychosocial-interventions-for-alcohol-use-disorder-a-review-of-efficacy-mechani-769467221db9db3bPharma Surgeen2026-07-10T00:00:00.000ZPsychosocial Interventions for Alcohol Use Disorder: A Review of Efficacy, Mechanisms, and Clinical Implicationshttps://www.pharmaradar360.com/article/polycystic-ovary-syndrome-pcos-polyendocrine-metabolic-ovarian-syndrome-pmos-res-d1a669b2c1b30e93Pharma Surgeen2026-07-10T00:00:00.000ZPolycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) Research Underfunding Continueshttps://www.pharmaradar360.com/article/perioperative-toripalimab-plus-chemotherapy-versus-chemotherapy-alone-in-locally-a3a8cbe121601c26Pharma Surgeen2026-07-10T00:00:00.000ZPerioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trialhttps://www.pharmaradar360.com/article/beyond-convenience-does-subcutaneous-pembrolizumab-add-value-for-patients-and-he-f4f03db17bbf288ePharma Surgeen2026-07-10T00:00:00.000ZBeyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?https://www.pharmaradar360.com/article/chemoradiotherapy-in-pancreatic-cancer-toward-precision-oncology-f4aed20c33bc2970Pharma Surgeen2026-07-10T00:00:00.000ZChemoradiotherapy in Pancreatic Cancer: Toward Precision Oncologyhttps://www.pharmaradar360.com/article/optimizing-antibiotic-use-for-cesarean-section-in-anticipation-of-the-diagnosis-ed0fa1701f02ed06Pharma Surgeen2026-07-10T00:00:00.000ZOptimizing antibiotic use for cesarean section in anticipation of the diagnosis-related groups payment system: a retrospective cohort study on the impact of clinical pharmacist interventionhttps://www.pharmaradar360.com/article/the-role-of-ai-assisted-drug-repurposing-in-neurological-disorders-a-systematic-a767880e39dd5fccPharma Surgeen2026-07-10T00:00:00.000ZThe role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunitieshttps://www.pharmaradar360.com/article/enhancing-perceived-clinical-competence-of-nursing-students-in-the-ai-era-the-ro-be802be8b4eb2861Pharma Surgeen2026-07-10T00:00:00.000ZEnhancing perceived clinical competence of nursing students in the AI era: the role of AI acceptance and self-directed learninghttps://www.pharmaradar360.com/article/optimizing-intermittent-preventive-treatment-for-malaria-in-pregnancy-protocol-f-d7366f85b850a8d8Pharma Surgeen2026-07-10T00:00:00.000ZOptimizing intermittent preventive treatment for malaria in pregnancy: protocol for phase IV randomized controlled trial of sulphadoxine–pyrimethamine, dihydroartemisinin–piperaquine, and combination therapy in Northern Nigeriahttps://www.pharmaradar360.com/article/clinical-features-antimicrobial-susceptibilities-and-outcomes-of-acute-onset-exo-b1c638b34385a077Pharma Surgeen2026-07-10T00:00:00.000ZClinical Features, Antimicrobial Susceptibilities, and Outcomes of Acute-Onset Exogenous Nocardia Endophthalmitishttps://www.pharmaradar360.com/article/remote-ischemic-conditioning-in-patients-with-acute-ischemic-stroke-ineligible-f-7834087166daf087Pharma Surgeen2026-07-10T00:00:00.000ZRemote Ischemic Conditioning in Patients With Acute Ischemic Stroke Ineligible for Recanalization Therapies: A Phase II Trialhttps://www.pharmaradar360.com/article/recommendations-for-assessing-methodological-quality-in-systematic-reviews-of-po-61aa75ef3db5046cPharma Surgeen2026-07-10T00:00:00.000ZRecommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Reviewhttps://www.pharmaradar360.com/article/clinical-determinants-of-discordance-between-estimated-glomerular-filtration-rat-5c73e3557f3fbcf3Pharma Surgeen2026-07-10T00:00:00.000ZClinical determinants of discordance between estimated glomerular filtration rates based on serum creatinine vs cystatin C in critically ill patientshttps://www.pharmaradar360.com/article/the-role-of-central-regulators-in-lipid-hydroperoxide-mediated-muscle-atrophy-ex-e8cfe482b60864e0Pharma Surgeen2026-07-10T00:00:00.000ZThe role of central regulators in lipid hydroperoxide-mediated muscle atrophy. Exploring mechanisms beyond ferroptosishttps://www.pharmaradar360.com/article/a-higher-start-red-criteria-count-at-emergency-department-arrival-is-associated-b8895e97b30c8b5aPharma Surgeen2026-07-10T00:00:00.000ZA higher START red-criteria count at emergency department arrival is associated with increased 28-day mortality in the CRASH-2 trialhttps://www.pharmaradar360.com/article/clinical-and-radiographic-performance-of-immediately-placed-and-immediately-prov-a751cd9a5e6cf857Pharma Surgeen2026-07-10T00:00:00.000ZClinical and radiographic performance of immediately-placed and immediately-provisionalised dental implants with a co-axial, inverted body-shift designhttps://www.pharmaradar360.com/article/cardioprotective-actions-of-metformin-in-myocardial-infarction-molecular-mechani-d477791b3948095cPharma Surgeen2026-07-10T00:00:00.000ZCardioprotective Actions of Metformin in Myocardial Infarction: Molecular Mechanisms and Clinical Perspectiveshttps://www.pharmaradar360.com/article/prolonged-migraine-aura-with-complete-symptom-resolution-revealing-unexpected-in-3ddd61ea02622559Pharma Surgeen2026-07-10T00:00:00.000ZProlonged Migraine Aura with Complete Symptom Resolution Revealing Unexpected Infarction: A Case Reporthttps://www.pharmaradar360.com/article/mindfulness-oriented-interventions-for-depressive-symptoms-in-non-clinical-young-6ce458b2c1865de4Pharma Surgeen2026-07-10T00:00:00.000ZMindfulness-Oriented Interventions for Depressive Symptoms in Non-clinical Young Adults: A Systematic Reviewhttps://www.pharmaradar360.com/article/non-invasive-pressure-flow-testing-validity-utility-and-clinical-integration-2ac04bbc7099c1b5Pharma Surgeen2026-07-10T00:00:00.000ZNON-Invasive Pressure Flow Testing: Validity, Utility, and Clinical Integrationhttps://www.pharmaradar360.com/article/comparative-effects-of-low-level-laser-acupuncture-and-dry-needling-on-clinical-60dd7d37a43c8f3cPharma Surgeen2026-07-10T00:00:00.000ZComparative effects of low-level laser acupuncture and dry needling on clinical and functional outcomes in patients with chronic cervical myofascial pain syndrome: a randomized controlled trialhttps://www.pharmaradar360.com/article/reply-to-the-comment-on-dalbavancin-for-infective-endocarditis-a-systematic-revi-2cfffad8417974d2Pharma Surgeen2026-07-10T00:00:00.000ZReply to the comment on: “Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing”https://www.pharmaradar360.com/article/single-cell-hdwgcna-identifies-checkpoint-inhibitor-pneumonitis-linked-cd4-t-cel-f0b9e527d923bc13Pharma Surgeen2026-07-10T00:00:00.000ZSingle-cell hdWGCNA identifies checkpoint inhibitor pneumonitis-linked CD4 + T-cell subsets driving immunotherapy response and prognosis in lung cancerhttps://www.pharmaradar360.com/article/unicompartmental-knee-arthroplasty-and-total-knee-arthroplasty-in-patients-with-fe22f62e9979fc3fPharma Surgeen2026-07-10T00:00:00.000ZUnicompartmental knee arthroplasty and total knee arthroplasty in patients with 15 or more degrees of varus deformity: age- and gender-matched comparative study of radiographic and clinical outcomeshttps://www.pharmaradar360.com/article/physiologically-based-pharmacokinetic-modeling-of-cefotaxime-to-inform-pediatric-856881605a4eea0cPharma Surgeen2026-07-10T00:00:00.000ZPhysiologically based pharmacokinetic modeling of cefotaxime to inform pediatric dosing in renal impairmenthttps://www.pharmaradar360.com/article/efficacy-and-safety-of-intravenous-ferric-carboxymaltose-versus-oral-iron-in-pre-ba69b7023a88e034Pharma Surgeen2026-07-10T00:00:00.000ZEfficacy and safety of intravenous ferric carboxymaltose versus oral iron in pregnant women with anemia: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/refining-fib-4-based-risk-stratification-in-adverse-drug-reactions-d1f02c35391d0b10Pharma Surgeen2026-07-10T00:00:00.000ZRefining FIB-4-based risk stratification in adverse drug reactionshttps://www.pharmaradar360.com/article/nail-surgery-in-children-specific-challenges-and-practical-considerations-346f7ce9f4a831d5Pharma Surgeen2026-07-10T00:00:00.000ZNail Surgery in Children: Specific Challenges and Practical Considerationshttps://www.pharmaradar360.com/article/ceftriaxone-induced-liver-injury-incidence-phenotypic-characterization-and-predi-3c49da3962fdda59Pharma Surgeen2026-07-10T00:00:00.000ZCeftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factorshttps://www.pharmaradar360.com/article/ethyl-difluoroacetate-market-demand-to-accelerate-by-2035-on-pharmaceutical-and-442074934afee31aPharma Surgeen2026-07-09T23:56:11.000ZEthyl Difluoroacetate Market Demand to Accelerate by 2035 on Pharmaceutical and Semiconductor Tailwindshttps://www.pharmaradar360.com/article/the-bull-case-for-west-pharmaceutical-services-wst-could-change-following-its-q1-e83216102c2bba3dPharma Surgeen2026-07-09T23:39:27.000ZThe Bull Case For West Pharmaceutical Services (WST) Could Change Following Its Q1 2026 Earnings Beat And Upgrades - Learn Whyhttps://www.pharmaradar360.com/article/ministers-launch-crackdown-on-vapes-targeting-kids-a8ae5b715136ed83Pharma Surgeen2026-07-09T23:15:02.000ZMinisters launch crackdown on vapes targeting kidshttps://www.pharmaradar360.com/article/new-uk-cmo-activity-guidelines-show-every-movement-counts-06b1c4794b8b6dedPharma Surgeen2026-07-09T23:15:00.000ZNew UK CMO activity guidelines show every movement countshttps://www.pharmaradar360.com/article/hlb-hits-new-fda-setback-as-hansoh-plant-issues-stall-liver-cancer-drug-chosunbi-df400fbef74090bfPharma Surgeen2026-07-09T23:13:00.000ZHLB hits new FDA setback as Hansoh plant issues stall liver cancer drug - CHOSUNBIZhttps://www.pharmaradar360.com/article/physical-activity-guidelines-uk-chief-medical-officers-report-cc1ca10ba3ba8515Pharma Surgeen2026-07-09T23:01:05.000ZPhysical activity guidelines: UK Chief Medical Officers' reporthttps://www.pharmaradar360.com/article/physical-activity-guidelines-pregnancy-and-after-childbirth-195d2b08fdc77ffbPharma Surgeen2026-07-09T23:01:05.000ZPhysical activity guidelines: pregnancy and after childbirthhttps://www.pharmaradar360.com/article/physical-activity-guidelines-early-years-under-5s-93de9a428b7393ffPharma Surgeen2026-07-09T23:01:05.000ZPhysical activity guidelines: early years (under 5s)https://www.pharmaradar360.com/article/physical-activity-guidelines-disabled-adults-e5b4126ee40a356bPharma Surgeen2026-07-09T23:01:05.000ZPhysical activity guidelines: disabled adultshttps://www.pharmaradar360.com/article/physical-activity-guidelines-children-and-young-people-5-to-18-years-eb1510c88ccd3c58Pharma Surgeen2026-07-09T23:01:05.000ZPhysical activity guidelines: children and young people (5 to 18 years)https://www.pharmaradar360.com/article/physical-activity-guidelines-adults-and-older-adults-24dfd3484d3377c6Pharma Surgeen2026-07-09T23:01:05.000ZPhysical activity guidelines: adults and older adultshttps://www.pharmaradar360.com/article/dianthus-therapeutics-dnth-starts-phase-3-emerge-trial-is-the-upside-already-pri-9ca45ad1f6bf1202Pharma Surgeen2026-07-09T22:41:07.000ZDianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In?https://www.pharmaradar360.com/article/9-of-the-top-10-pharma-manufacturers-partner-with-redi-health-to-lead-the-next-g-687e9ffbfdb37833Pharma Surgeen2026-07-09T21:51:48.000Z9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experiencehttps://www.pharmaradar360.com/article/sino-and-astrazeneca-sign-licence-agreement-for-tqc3721-ede08d1ecad9675fPharma Surgeen2026-07-09T21:51:00.000ZSino and AstraZeneca sign licence agreement for TQC3721https://www.pharmaradar360.com/article/day-7-alj-hearing-prominent-pain-physician-calls-state-medical-marijuana-system-a3b21544b48b5c80Pharma Surgeen2026-07-09T21:20:00.000ZDay 7 ALJ Hearing: Prominent Pain Physician Calls State Medical Marijuana System a Rusehttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-a-disease-modeling-research-grant-and-an-accelerator-progr-136f87ff3f13b024Pharma Surgeen2026-07-09T21:13:08.000ZThe biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-upshttps://www.pharmaradar360.com/article/fda-approves-ennumo-pharmexec-21caa110d06d2dffPharma Surgeen2026-07-09T21:07:29.000ZFDA Approves Ennumo | PharmExechttps://www.pharmaradar360.com/article/biotech-in-burnham-s-britain-1cce86c628c0a117Pharma Surgeen2026-07-09T20:43:00.000ZBiotech in Burnham’s Britainhttps://www.pharmaradar360.com/article/women-who-say-they-experienced-harm-from-abortion-pill-push-blanche-to-settle-su-70fb53afab44830fPharma Surgeen2026-07-09T20:30:53.000ZWomen who say they experienced harm from abortion pill push Blanche to settle suit on FDA policyhttps://www.pharmaradar360.com/article/national-coalition-of-pharmaceutical-industry-academic-and-nonprofit-partners-la-67b89a4626422517Pharma Surgeen2026-07-09T20:28:43.000ZNational Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners launches fifth Winn CIPP Cohorthttps://www.pharmaradar360.com/article/does-america-s-new-favorite-anxiety-drug-have-a-dark-side-164fe18070cccd82Pharma Surgeen2026-07-09T20:15:17.000ZDoes America's New Favorite Anxiety Drug Have a Dark Side?https://www.pharmaradar360.com/article/amneal-to-report-second-quarter-2026-results-on-july-30-2026-4f8c92a3242a5a25Pharma Surgeen2026-07-09T20:05:00.000ZAmneal to Report Second Quarter 2026 Results on July 30, 2026https://www.pharmaradar360.com/article/bridgebio-pharma-bbio-jumps-on-trial-win-and-1b-raise-2dee51eb29868edbPharma Surgeen2026-07-09T20:03:00.000ZBridgeBio Pharma BBIO Jumps On Trial Win And $1B Raisehttps://www.pharmaradar360.com/article/nurix-lands-700m-roche-payment-as-cll-drug-expands-cee9d79feb627f82Pharma Surgeen2026-07-09T20:01:00.000ZNurix lands $700M Roche payment as CLL drug expandshttps://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-after-its-massive-rally-b2a5996adc658fdePharma Surgeen2026-07-09T20:00:00.000ZIs This Biotech Stock a Buy After Its Massive Rally?https://www.pharmaradar360.com/article/invesco-pharmaceuticals-etf-vs-state-street-biotech-etf-which-fund-is-the-better-f972b84c0c037c00Pharma Surgeen2026-07-09T19:47:00.000ZInvesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?https://www.pharmaradar360.com/article/bpi-s-mid-year-report-highlights-2026-biotech-trends-c7e3624a16e62a66Pharma Surgeen2026-07-09T19:31:37.000ZBPI's mid-year report highlights 2026 biotech trendshttps://www.pharmaradar360.com/article/erlc-signs-letter-urging-acting-ag-blanche-to-resolve-abortion-drug-lawsuit-a182d84cbef5ead0Pharma Surgeen2026-07-09T19:16:31.000ZERLC Signs Letter Urging Acting AG Blanche to Resolve Abortion Drug Lawsuithttps://www.pharmaradar360.com/article/invesco-pharmaceuticals-etf-vs-state-street-biotech-etf-which-fund-is-the-better-ba6a428f3d69b19cPharma Surgeen2026-07-09T19:07:25.000ZInvesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?https://www.pharmaradar360.com/article/roche-ends-2-huntington-s-programs-including-ionis-aso-fd82e2b0ba6173e2Pharma Surgeen2026-07-09T18:40:16.000ZRoche ends 2 Huntington’s programs, including Ionis ASOhttps://www.pharmaradar360.com/article/biotech-stock-arcutis-climbs-into-buy-zone-as-fda-mulls-expanded-use-for-key-ski-23a90bdd479371cfPharma Surgeen2026-07-09T17:37:00.000ZBiotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatmenthttps://www.pharmaradar360.com/article/fda-grants-tegacorat-orphan-rare-pediatric-disease-status-for-dmd-fa9441a2d28fede4Pharma Surgeen2026-07-09T17:22:13.000ZFDA grants tegacorat orphan, rare pediatric disease status for DMDhttps://www.pharmaradar360.com/article/novartis-vs-teva-which-pharmaceutical-stock-is-a-better-buy-in-2026-6c30d9906a14af66Pharma Surgeen2026-07-09T17:12:00.000ZNovartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/fda-greenlights-phase-1-study-of-ugn-501-for-nmibc-232202ac70168053Pharma Surgeen2026-07-09T17:11:47.000ZFDA greenlights phase 1 study of UGN-501 for NMIBChttps://www.pharmaradar360.com/article/stocks-look-shaky-but-this-sector-is-booming-biotech-5fb172137f1bec27Pharma Surgeen2026-07-09T17:04:00.000ZStocks Look Shaky, But This Sector is Booming (Biotech)https://www.pharmaradar360.com/article/mumbai-s-iconic-k-rustom-ice-cream-outlet-shut-after-rats-expired-stock-found-d29008f7b0f37e25Pharma Surgeen2026-07-09T16:26:36.000ZMumbai's iconic K Rustom ice cream outlet shut after rats, expired stock foundhttps://www.pharmaradar360.com/article/why-the-direct-model-is-the-future-of-pharma-1-fcd00c1bcd20f657Pharma Surgeen2026-07-09T16:13:12.000ZWhy the Direct Model is the Future of Pharma(1)https://www.pharmaradar360.com/article/stocks-look-shaky-but-this-sector-is-booming-biotech-1e36968c8e4376a9Pharma Surgeen2026-07-09T16:11:04.000ZStocks Look Shaky, But This Sector is Booming (Biotech)https://www.pharmaradar360.com/article/jim-cramer-says-biotech-is-the-hottest-group-in-the-market-right-now-b97b6d1fc82fb58dPharma Surgeen2026-07-09T15:46:21.000ZJim Cramer Says Biotech is The Hottest Group in The Market Right Nowhttps://www.pharmaradar360.com/article/why-the-pharmacy-experience-matters-for-glp-1-outcomes-d9876092ad73a96bPharma Surgeen2026-07-09T15:38:12.000ZWhy the Pharmacy Experience Matters for GLP-1 Outcomeshttps://www.pharmaradar360.com/article/jim-cramer-says-biotech-is-the-hottest-group-in-the-market-right-now-185cba1a3e3178b0Pharma Surgeen2026-07-09T15:35:25.000ZJim Cramer Says Biotech is The Hottest Group in The Market Right Nowhttps://www.pharmaradar360.com/article/anti-vegf-biosimilars-match-reference-drug-in-indian-retinal-disease-care-f6d123e027946f64Pharma Surgeen2026-07-09T15:34:10.000ZAnti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Carehttps://www.pharmaradar360.com/article/vivani-s-semaglutide-implant-advances-to-human-testing-823c81a3454f4d5ePharma Surgeen2026-07-09T15:13:11.000ZVivani's Semaglutide Implant Advances to Human Testinghttps://www.pharmaradar360.com/article/as-ramaswamy-vacations-in-europe-biotech-he-founded-collects-950m-covid-vaccine-883ac449d0ed0a52Pharma Surgeen2026-07-09T15:10:00.000ZAs Ramaswamy vacations in Europe, biotech he founded collects $950M COVID vaccine paymenthttps://www.pharmaradar360.com/article/arialys-therapeutics-announces-u-s-fda-fast-track-designation-for-art5803-the-fi-44d0d3cc6ba0be70Pharma Surgeen2026-07-09T15:08:09.000ZArialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitishttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-63ff575955c0b169Pharma Surgeen2026-07-09T15:07:56.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, October 2026 to October 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-dd9b886471b7e27ePharma Surgeen2026-07-09T15:07:39.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, September 2026 to September 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-e29136a0758c031fPharma Surgeen2026-07-09T15:07:28.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2026 to August 2027https://www.pharmaradar360.com/article/depression-drug-approved-by-fda-had-11-failed-trials-and-an-advisory-committee-v-fb6743728e10c812Pharma Surgeen2026-07-09T15:07:28.000ZDepression Drug Approved by FDA Had 11 Failed Trials and an Advisory Committee Vote Against Approvalhttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-e4a658a591d9a33ePharma Surgeen2026-07-09T15:07:15.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, July 2026 to July 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-a0324311fd4d4714Pharma Surgeen2026-07-09T15:07:01.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, June 2026 to June 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-2e45bd7b86003737Pharma Surgeen2026-07-09T15:06:38.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, May 2026 to May 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-b7f6f80136a72c29Pharma Surgeen2026-07-09T15:05:52.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, April 2026 to April 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-a9688d88c3a30590Pharma Surgeen2026-07-09T15:05:20.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, March 2026 to March 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-df1ca0002f7ddc6bPharma Surgeen2026-07-09T15:05:05.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, February 2026 to February 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-6665f6d4d545e2adPharma Surgeen2026-07-09T15:04:46.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, January 2026 to January 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-b514e806327cec75Pharma Surgeen2026-07-09T15:04:29.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, December 2025 to December 2026https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-9bc61a228a7791a8Pharma Surgeen2026-07-09T15:04:06.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, November 2025 to November 2026https://www.pharmaradar360.com/article/biocon-announces-peer-reviewed-data-supporting-yesafili-in-diabetic-macular-edem-4d330fc7fe1308c4Pharma Surgeen2026-07-09T14:57:07.000ZBiocon Announces Peer-Reviewed Data Supporting Yesafili in Diabetic Macular Edemahttps://www.pharmaradar360.com/article/nhs-resolution-annual-report-and-accounts-2025-to-2026-9fb1d190d44240abPharma Surgeen2026-07-09T14:57:03.000ZNHS Resolution annual report and accounts: 2025 to 2026https://www.pharmaradar360.com/article/structuring-tech-transfer-for-optimized-collaboration-f681cd65b348ed55Pharma Surgeen2026-07-09T14:41:34.000ZStructuring Tech Transfer for Optimized Collaborationhttps://www.pharmaradar360.com/article/uk-health-security-agency-ukhsa-research-involving-animals-d1a35b4ab386d009Pharma Surgeen2026-07-09T14:41:22.000ZUK Health Security Agency (UKHSA) research involving animalshttps://www.pharmaradar360.com/article/millions-of-risky-eye-drops-recalled-what-to-do-now-dd40cf310fba0ee3Pharma Surgeen2026-07-09T14:39:51.000ZMillions of risky eye drops recalled, what to do nowhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-95407ca4abeca4e9Pharma Surgeen2026-07-09T14:37:28.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/ipsen-s-botox-rival-dysport-charts-new-horizons-with-dual-phase-3-wins-in-migrai-49b7292d6cba9f01Pharma Surgeen2026-07-09T14:36:52.000ZIpsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migrainehttps://www.pharmaradar360.com/article/marburg-and-ebola-contact-tracing-matrix-86b4f06f6555d1e2Pharma Surgeen2026-07-09T14:30:00.000ZMarburg and Ebola contact tracing matrixhttps://www.pharmaradar360.com/article/crimean-congo-haemorrhagic-fever-cchf-contact-tracing-matrix-4a84aeef62e16262Pharma Surgeen2026-07-09T14:30:00.000ZCrimean-Congo haemorrhagic fever (CCHF) contact tracing matrixhttps://www.pharmaradar360.com/article/paxlovid-safe-for-children-aged-6-and-older-new-study-finds-c14e725c039055efPharma Surgeen2026-07-09T14:30:00.000ZPaxlovid Safe for Children Aged 6 And Older, New Study Findshttps://www.pharmaradar360.com/article/regulators-push-amgen-to-withdraw-drug-due-to-data-manipulation-ab29bf085d70abf5Pharma Surgeen2026-07-09T14:22:13.000ZRegulators push Amgen to withdraw drug due to data manipulationhttps://www.pharmaradar360.com/article/prime-wins-beam-arbitration-clearing-path-to-clinic-9394e079194e3638Pharma Surgeen2026-07-09T14:06:57.000ZPrime wins Beam arbitration, clearing path to clinichttps://www.pharmaradar360.com/article/lilly-was-already-pharma-s-biggest-company-now-it-s-doing-deals-to-match-7051dfd83f0d8e5aPharma Surgeen2026-07-09T14:00:00.000ZLilly was already pharma's biggest company. Now it's doing deals to matchhttps://www.pharmaradar360.com/article/serum-institute-of-india-ties-up-with-dndi-for-phase-iii-trial-of-dengue-therapy-82db2368ff3edeccPharma Surgeen2026-07-09T13:58:26.000ZSerum Institute of India ties up with DNDi for Phase III trial of dengue therapyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-shijiazhuang-yiling-pharmaceutical-co-ltd-class-a-s-6c8686997a6409c5Pharma Surgeen2026-07-09T13:55:52.000ZPrice to earnings forward of Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A – SZSE:002603https://www.pharmaradar360.com/article/biotech-executive-keating-named-to-board-of-berkeley-heights-biopharma-kalaris-3f9a7b620670ea7bPharma Surgeen2026-07-09T13:43:29.000ZBiotech executive Keating named to board of Berkeley Heights biopharma Kalarishttps://www.pharmaradar360.com/article/astrazeneca-ionis-shares-slide-after-wainua-misses-target-in-heart-disease-trial-8916c763d718a7faPharma Surgeen2026-07-09T13:41:00.000ZAstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trialhttps://www.pharmaradar360.com/article/should-value-investors-buy-collegium-pharmaceutical-coll-stock-f7e57ce301393c87Pharma Surgeen2026-07-09T13:40:04.000ZShould Value Investors Buy Collegium Pharmaceutical (COLL) Stock?https://www.pharmaradar360.com/article/access-new-active-substance-and-biosimilar-work-sharing-initiatives-4389fa8c328281b5Pharma Surgeen2026-07-09T13:33:57.000ZAccess, new active substance and biosimilar work sharing initiativeshttps://www.pharmaradar360.com/article/why-biotech-revenue-projections-won-t-look-as-sunny-once-trump-tax-bill-hits-med-d3e9354ebdb0f2f0Pharma Surgeen2026-07-09T13:28:38.000ZWhy biotech revenue projections ‘won’t look as sunny’ once Trump tax bill hits Medicaid enrollmenthttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-12-month-price-target-raised-to-370-23-im-8914a8d9390a32d2Pharma Surgeen2026-07-09T13:20:15.000ZWest Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $370.23, Implies 5% Upsidehttps://www.pharmaradar360.com/article/health-research-authority-annual-report-and-accounts-2025-to-2026-b267f58dcd06ad06Pharma Surgeen2026-07-09T13:12:10.000ZHealth Research Authority annual report and accounts 2025 to 2026https://www.pharmaradar360.com/article/roche-ends-two-huntington-s-disease-drug-programmes-after-disappointing-results-33baea7041472f72Pharma Surgeen2026-07-09T13:01:00.000ZRoche ends two Huntington’s disease drug programmes after disappointing resultshttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2025-to-2026-695ba9f5e6b7fd05Pharma Surgeen2026-07-09T13:00:03.000ZWeekly all-cause mortality surveillance: 2025 to 2026https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-09T13:00:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-09T13:00:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-09T13:00:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-09T13:00:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-09T13:00:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-09T13:00:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/it-s-time-to-build-a-more-scalable-connected-cro-6ee6a0c53fad1759Pharma Surgeen2026-07-09T12:56:53.000ZIt’s Time to Build a More Scalable, Connected CROhttps://www.pharmaradar360.com/article/wst-completes-smartdose-sale-to-abbvie-to-focus-on-core-growth-57c59d7fcaa24c27Pharma Surgeen2026-07-09T12:56:00.000ZWST Completes SmartDose Sale to AbbVie to Focus on Core Growthhttps://www.pharmaradar360.com/article/astrazeneca-licenses-sino-biopharma-respiratory-drug-in-200-million-upfront-deal-5e59d611cccc6e4aPharma Surgeen2026-07-09T12:49:45.000ZAstraZeneca licenses Sino Biopharma respiratory drug in $200 million upfront dealhttps://www.pharmaradar360.com/article/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-01af34cc5d056313Pharma Surgeen2026-07-09T12:45:15.000ZFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidatehttps://www.pharmaradar360.com/article/opus-genetics-expects-september-data-from-gene-therapy-trial-by-investing-com-5765fbf7922f8b30Pharma Surgeen2026-07-09T12:44:07.000ZOpus Genetics expects September data from gene therapy trial By Investing.comhttps://www.pharmaradar360.com/article/vanguard-health-care-vs-vaneck-pharmaceutical-how-do-these-etfs-stack-up-f56d45051d37992aPharma Surgeen2026-07-09T12:35:04.000ZVanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?https://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82cPharma Surgeen2026-07-09T12:34:24.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/fda-clears-fate-therapeutics-ft839-for-autoimmune-trial-push-7817185ed8a91721Pharma Surgeen2026-07-09T12:30:00.000ZFDA clears Fate Therapeutics' FT839 for autoimmune trial pushhttps://www.pharmaradar360.com/article/astrazeneca-ionis-drug-fails-big-heart-disease-study-in-major-setback-d7d028eb77ff8217Pharma Surgeen2026-07-09T12:17:37.000ZAstraZeneca, Ionis drug fails big heart disease study in major setbackhttps://www.pharmaradar360.com/article/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-diff-42744a8c3ba092ffPharma Surgeen2026-07-09T12:16:20.000ZAnnual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2026 to 2027https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-820ecbff0a7a966cPharma Surgeen2026-07-09T12:11:27.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2027https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-335870a76488db42Pharma Surgeen2026-07-09T12:10:59.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to January to March 2027https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-ae1ac0815b2896b3Pharma Surgeen2026-07-09T12:10:29.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to October to December 2026https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-bfc75e0710215140Pharma Surgeen2026-07-09T12:09:49.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to July to September 2026https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-476c46b5e267deccPharma Surgeen2026-07-09T12:09:22.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2026https://www.pharmaradar360.com/article/ca-auxilium-biotech-4dfdc6fde43e0d4ePharma Surgeen2026-07-09T12:03:21.000ZCA-AUXILIUM-BIOTECHhttps://www.pharmaradar360.com/article/zerostack-corp-secures-purchase-orders-for-up-to-us-14-7-million-of-inventory-fr-725b7f6698bda3e4Pharma Surgeen2026-07-09T12:01:00.000ZZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companieshttps://www.pharmaradar360.com/article/3-high-growth-glp-1-biotech-winners-to-buy-in-july-bff96628a3394d4aPharma Surgeen2026-07-09T12:00:59.000Z3 High Growth GLP-1 Biotech Winners to Buy in Julyhttps://www.pharmaradar360.com/article/phantom-hindfoot-ttc-tc-ball-tipped-guide-rod-50350c992cf9e824Pharma Surgeen2026-07-09T12:00:00.000ZPhantom® Hindfoot TTC/TC Ball Tipped Guide Rodhttps://www.pharmaradar360.com/article/om-warmer-d2e822d1212b5d63Pharma Surgeen2026-07-09T12:00:00.000ZºM Warmerhttps://www.pharmaradar360.com/article/astral-150tm-6eae77da267f4c7bPharma Surgeen2026-07-09T12:00:00.000ZAstral 150™https://www.pharmaradar360.com/article/research-use-of-uk-plasma-for-the-manufacture-of-five-further-plasma-derived-med-16a48978081dad48Pharma Surgeen2026-07-09T11:55:12.000ZResearch: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD riskhttps://www.pharmaradar360.com/article/pharmaceutical-technology-fe6a0a6f5e104550Pharma Surgeen2026-07-09T11:55:10.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/carbapenemase-producing-gram-negative-organisms-laboratory-surveillance-2476b0d93f0c3ea1Pharma Surgeen2026-07-09T11:52:29.000ZCarbapenemase-producing Gram-negative organisms: laboratory surveillancehttps://www.pharmaradar360.com/article/vertex-acquires-crinetics-in-10bn-endocrinology-deal-955b8f9fcbe04ad8Pharma Surgeen2026-07-09T11:36:29.000ZVertex acquires Crinetics in $10bn endocrinology dealhttps://www.pharmaradar360.com/article/us-fda-approves-first-in-class-treatment-for-kidney-disease-76bad0acea46ee22Pharma Surgeen2026-07-09T11:36:18.000ZUS FDA approves first-in-class treatment for kidney diseasehttps://www.pharmaradar360.com/article/the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-5105a372fc283456Pharma Surgeen2026-07-09T11:35:51.000ZThe Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rushhttps://www.pharmaradar360.com/article/gsk-cuts-losses-on-700m-upfront-alzheimer-s-collab-with-alector-following-2-clin-873f91b19acd8a25Pharma Surgeen2026-07-09T11:30:52.000ZGSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failureshttps://www.pharmaradar360.com/article/lilly-to-present-alzheimer-s-disease-diagnostic-and-therapeutic-research-at-aaic-d02eb15f8fa54358Pharma Surgeen2026-07-09T11:30:00.000ZLilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatmenthttps://www.pharmaradar360.com/article/isaaa-launches-brief-57-in-manila-marking-two-decades-of-biotech-success-in-the-7b80dc8fda17251ePharma Surgeen2026-07-09T11:29:24.000ZISAAA Launches Brief 57 in Manila, Marking Two Decades of Biotech Success in the Philippineshttps://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49bPharma Surgeen2026-07-09T11:26:53.000ZHealth protection in children and young people's settings, including educationhttps://www.pharmaradar360.com/article/cordis-project-accelerating-stroke-treatment-innovation-through-an-ai-enabled-in-1a5df07ae8e5e0b2Pharma Surgeen2026-07-09T11:24:34.000ZCORDIS project: ACCELERATING STROKE TREATMENT INNOVATION THROUGH AN AI-ENABLED IN-SILICO NEW APPROACH METHODOLOGY (NAM)https://www.pharmaradar360.com/article/cordis-project-reconfigurable-colloids-for-therapeutic-applications-64a9199daded6a23Pharma Surgeen2026-07-09T11:24:30.000ZCORDIS project: Reconfigurable Colloids For Therapeutic Applicationshttps://www.pharmaradar360.com/article/cordis-project-ultra-scalable-genetic-programming-for-nam-ready-engineered-myoti-366cb2a8e45a21e5Pharma Surgeen2026-07-09T11:24:06.000ZCORDIS project: Ultra-Scalable Genetic Programming for NAM-Ready Engineered Myotissueshttps://www.pharmaradar360.com/article/cordis-project-iris-vista-from-proof-of-concept-to-market-readiness-in-predictiv-4ceff8cb83d4db78Pharma Surgeen2026-07-09T11:24:05.000ZCORDIS project: IRIS-VISTA: From Proof-of-Concept to Market Readiness in Predictive Neurovascular Medicinehttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-09T11:22:09.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/3-reasons-to-buy-novo-nordisk-stock-6a25836f53ed473fPharma Surgeen2026-07-09T11:16:50.000Z3 Reasons to Buy Novo Nordisk Stockhttps://www.pharmaradar360.com/article/illicit-gain-combating-commission-widens-scope-placing-private-pharmaceutical-an-75eb0ecd2b029c16Pharma Surgeen2026-07-09T11:09:18.000ZIllicit Gain Combating Commission widens scope, placing private pharmaceutical and higher education institutions under direct controlhttps://www.pharmaradar360.com/article/science-in-motion-the-technologies-shaping-tomorrow-s-pharmaceutical-industry-e8c79cff4cdac921Pharma Surgeen2026-07-09T10:42:45.000ZScience in Motion: The Technologies Shaping Tomorrow's Pharmaceutical Industryhttps://www.pharmaradar360.com/article/30-2026-0da497c6889855bfPharma Surgeen2026-07-09T10:39:18.000ZΑΝΑΡΤΗΣΗ ΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 30 ΙΟΥΝΙΟΥ 2026https://www.pharmaradar360.com/article/teva-teva-advances-tev-408-into-phase-2b-for-vitiligo-after-early-progress-a0cc222fb5e8994ePharma Surgeen2026-07-09T10:37:40.000ZTeva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progresshttps://www.pharmaradar360.com/article/teva-teva-advances-tev-408-into-phase-2b-for-vitiligo-after-early-progress-544b715b3694bf23Pharma Surgeen2026-07-09T10:37:39.000ZTeva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progresshttps://www.pharmaradar360.com/article/is-viking-therapeutics-stock-going-to-100-a586155229d5e8b1Pharma Surgeen2026-07-09T10:37:09.000ZIs Viking Therapeutics Stock Going to $100?https://www.pharmaradar360.com/article/931-days-the-drug-approval-scandal-hiding-in-plain-sight-d7cbcfd237196033Pharma Surgeen2026-07-09T10:31:53.000Z931 days. The drug approval scandal hiding in plain sighthttps://www.pharmaradar360.com/article/biotech-s-digital-twin-dilemma-33b1623e57b488fdPharma Surgeen2026-07-09T10:30:28.000ZBiotech’s digital twin dilemmahttps://www.pharmaradar360.com/article/greenwood-capital-associates-llc-sells-142-082-shares-of-teva-pharmaceutical-ind-a2069f81be85211aPharma Surgeen2026-07-09T10:27:15.000ZGreenwood Capital Associates LLC Sells 142,082 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/pharmaceutical-packaging-summit-2026-3d9f9694a6622fe3Pharma Surgeen2026-07-09T10:25:31.000ZPharmaceutical Packaging Summit 2026https://www.pharmaradar360.com/article/evonik-invests-100-million-in-u-s-api-production-42c347c9fe6c8692Pharma Surgeen2026-07-09T10:13:39.000ZEvonik Invests $100 Million in U.S. API Productionhttps://www.pharmaradar360.com/article/class-2-medicines-recall-bristol-laboratories-limited-phenoxymethylpenicillin-25-01eaedddca8554b6Pharma Surgeen2026-07-09T10:07:16.000ZClass 2 Medicines Recall: Bristol Laboratories Limited, Phenoxymethylpenicillin 250 mg/5ml Sugar free Oral Solution BP, EL(26)A/33https://www.pharmaradar360.com/article/roy-jakobs-to-join-gsk-board-as-non-executive-director-cb0d5a54ca69147cPharma Surgeen2026-07-09T10:00:00.000ZRoy Jakobs to join GSK Board as Non-Executive Directorhttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-09T09:52:04.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/3bf4b717e6b46efbPharma Surgeen2026-07-09T09:47:56.000ZΕπαναδιατύπωση και Ανάρτηση Πρόσκλησης Εκδήλωσης Ενδιαφέροντος για Συνεργασία με Καθεστώς Α.Π.Υ. (Ορθή Επανάληψη)https://www.pharmaradar360.com/article/china-s-ascent-in-biotech-rousts-u-s-venture-capitalists-to-adapt-1a5c293d73b4074bPharma Surgeen2026-07-09T09:30:00.000ZChina’s Ascent in Biotech Rousts U.S. Venture Capitalists to Adapthttps://www.pharmaradar360.com/article/live-rats-houseflies-fda-suspends-license-of-mumbai-s-iconic-rustom-ice-cream-pa-3c2e88247ecf16c7Pharma Surgeen2026-07-09T09:30:00.000ZLive rats, houseflies: FDA suspends license of Mumbai's iconic 'Rustom' ice cream parlour over food safety violationshttps://www.pharmaradar360.com/article/pharmaceutical-industry-adopts-disease-classification-for-obesity-to-align-with-375b1a876faf7cc0Pharma Surgeen2026-07-09T09:19:17.000ZPharmaceutical Industry Adopts Disease Classification for Obesity to Align with GLP-1 Medication Markethttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-12432027a49613e7Pharma Surgeen2026-07-09T08:58:43.000ZDHSC spending over £25,000https://www.pharmaradar360.com/article/dhsc-spending-over-25-000-march-2026-4ecb811897116b1ePharma Surgeen2026-07-09T08:58:12.000ZDHSC: spending over £25,000, March 2026https://www.pharmaradar360.com/article/dhsc-spending-over-25-000-april-2026-7a14df1ff5986eabPharma Surgeen2026-07-09T08:58:07.000ZDHSC: spending over £25,000, April 2026https://www.pharmaradar360.com/article/global-biotech-leaders-converge-at-uab-s-bac-2026-e11c4238554def98Pharma Surgeen2026-07-09T08:58:00.000ZGlobal Biotech Leaders Converge at UAB's BAC 2026https://www.pharmaradar360.com/article/does-tango-therapeutics-tngx-russell-growth-shift-reveal-its-true-biotech-identi-ddcebee6d0f6e18fPharma Surgeen2026-07-09T08:46:34.000ZDoes Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-tibet-rhodiola-pharmaceutical-holding-co-c-61effe861e03dfebPharma Surgeen2026-07-09T08:42:49.000ZEnterprise value to EBITDA forward of Tibet Rhodiola Pharmaceutical Holding Co. Class A – SSE:600211https://www.pharmaradar360.com/article/biotech-rally-rests-on-fundamentals-m-a-appetite-says-roty-s-faison-xlv-nysearca-4617a6dfa8480c43Pharma Surgeen2026-07-09T08:33:52.000ZBiotech rally rests on fundamentals, M&A appetite, says ROTY's Faison (XLV:NYSEARCA)https://www.pharmaradar360.com/article/the-quest-to-save-grace-and-clear-the-way-for-rare-disease-patients-everywhere-5c8d5ca3d7dce25fPharma Surgeen2026-07-09T08:31:50.000ZThe quest to save Grace — and clear the way for rare disease patients everywherehttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-09T08:30:15.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-09T08:30:15.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-07-09T08:30:14.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884Pharma Surgeen2026-07-09T08:30:13.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-09T08:30:12.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/life-sciences-jobs-plan-7418017e22c905c6Pharma Surgeen2026-07-09T08:30:12.000ZLife Sciences Jobs Planhttps://www.pharmaradar360.com/article/virus-reference-department-vrd-user-manual-bad0eec46821b469Pharma Surgeen2026-07-09T08:30:11.000ZVirus Reference Department (VRD): user manualhttps://www.pharmaradar360.com/article/measles-historic-confirmed-cases-notifications-and-deaths-55822ba8c9246f07Pharma Surgeen2026-07-09T08:30:09.000ZMeasles: Historic confirmed cases, notifications and deathshttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report-2955927e098c6836Pharma Surgeen2026-07-09T08:30:05.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: quarterly reporthttps://www.pharmaradar360.com/article/ukhsa-evidence-reviews-8f54ff16e8d4cd78Pharma Surgeen2026-07-09T08:30:05.000ZUKHSA evidence reviewshttps://www.pharmaradar360.com/article/hand-hygiene-alternatives-to-soap-and-water-for-reducing-c-difficile-c51d2f2eaee482cdPharma Surgeen2026-07-09T08:30:03.000ZHand hygiene alternatives to soap and water for reducing C. difficilehttps://www.pharmaradar360.com/article/fda-plan-could-put-pharma-ads-out-of-reach-for-broadcasters-f66838d8b17a7d21Pharma Surgeen2026-07-09T08:30:00.000ZFDA Plan Could Put Pharma Ads Out Of Reach For Broadcasters.https://www.pharmaradar360.com/article/medipost-enrolls-and-treats-first-patient-in-u-s-phase-3-trial-of-cartistem-adva-cff97f3699db3787Pharma Surgeen2026-07-09T08:14:40.000ZMEDIPOST enrolls and treats first patient in U.S. Phase 3 trial of CARTISTEM, advancing U.S. commercializationhttps://www.pharmaradar360.com/article/astrazeneca-stock-drops-9-after-heart-drug-trial-miss-deals-rare-blow-to-pharma-9af4350aaad58778Pharma Surgeen2026-07-09T07:34:08.000ZAstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhousehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-moleculin-biotech-inc-nasdaq-mbrx-47e569ad7fa0c6c9Pharma Surgeen2026-07-09T07:12:52.000ZEnterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRXhttps://www.pharmaradar360.com/article/pharmaceutical-machine-learning-market-growth-to-accelerate-by-2035-amid-ai-driv-85facc4026702819Pharma Surgeen2026-07-09T07:06:10.000ZPharmaceutical Machine Learning Market Growth to Accelerate by 2035 Amid AI-Driven Bioprocessing Advances - News and Statisticshttps://www.pharmaradar360.com/article/when-two-cros-become-one-sites-pay-the-integration-tax-d457fb0c051540daPharma Surgeen2026-07-09T06:53:13.000ZWhen Two CROs Become One, Sites Pay the Integration Taxhttps://www.pharmaradar360.com/article/setmelanotide-phase-3-trial-for-hypothalamic-obesity-published-in-nejm-50b9d1d1e1f5dfd1Pharma Surgeen2026-07-09T06:53:13.000ZSetmelanotide Phase 3 Trial for Hypothalamic Obesity Published in NEJMhttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-beauty-creams-after-tests-detect-excessive-m-3eb658af4516b369Pharma Surgeen2026-07-09T06:48:58.000ZMaharashtra FDA Warns Against Three Beauty Creams after Tests Detect Excessive Mercury, Lead Levelshttps://www.pharmaradar360.com/article/fda-accepts-arcutis-zoryve-application-for-atopic-dermatitis-in-3-month-old-infa-f8e539eda1ebd9a8Pharma Surgeen2026-07-09T06:48:13.000ZFDA Accepts Arcutis ZORYVE Application for Atopic Dermatitis in 3-Month-Old Infantshttps://www.pharmaradar360.com/article/sunscreen-monograph-fda-adds-bemotrizinol-in-latest-update-4f568e05c16a4d70Pharma Surgeen2026-07-09T06:37:20.000ZSunscreen Monograph: FDA Adds Bemotrizinol in Latest Updatehttps://www.pharmaradar360.com/article/ionis-heart-drug-misses-key-goal-but-monotherapy-subgroup-hit-0cee8281df71d1dcPharma Surgeen2026-07-09T06:30:27.000ZIonis heart drug misses key goal, but monotherapy subgroup hithttps://www.pharmaradar360.com/article/novo-nordisk-launches-weekly-insulin-shot-awiqli-in-india-8e6e52751e41790ePharma Surgeen2026-07-09T06:23:00.000ZNovo Nordisk launches weekly insulin shot Awiqli in Indiahttps://www.pharmaradar360.com/article/accelerated-amortized-payment-of-convertible-bond-installment-c6b37637350b9310Pharma Surgeen2026-07-09T06:16:32.000ZAccelerated Amortized Payment of Convertible Bond Installmenthttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jointown-pharmaceutical-group-co-ltd-class-7fd9ca5c8f554de8Pharma Surgeen2026-07-09T06:10:53.000ZEnterprise value to EBITDA forward of Jointown Pharmaceutical Group Co., Ltd. Class A – SSE:600998https://www.pharmaradar360.com/article/price-to-sales-forward-of-ningbo-menovo-pharmaceutical-co-ltd-class-a-sse-603538-2096f17cc25616f7Pharma Surgeen2026-07-09T06:05:03.000ZPrice to sales forward of Ningbo Menovo Pharmaceutical Co., Ltd. Class A – SSE:603538https://www.pharmaradar360.com/article/update-on-cardio-ttransform-phase-3-trial-of-eplontersen-in-adults-with-transthy-1b490718b10892e1Pharma Surgeen2026-07-09T06:00:00.000ZUpdate on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathyhttps://www.pharmaradar360.com/article/raman-spectroscopic-systems-market-growth-outlook-to-2035-pharmaceutical-and-sem-d90d1ee212bedba8Pharma Surgeen2026-07-09T05:51:10.000ZRaman Spectroscopic Systems Market Growth Outlook to 2035: Pharmaceutical and Semiconductor Verticals Lead Demand - News and Statistics